Pitch & Match
Through Pitch & Match, we provide our investors and presenting companies the opportunity to know each other before event day, get engaged through presentation, Q&A and arrange immediate follow-up meetings.
Presentation fees: $3000 （Includes presentation fee and one registration for presenter）
Presentation Companies Can:
- Meet pre-vetted decision makers from top Chinese pharma and investment firms
- Know your audience prior to the pitch
- Maximized your company visibility through pre-conference promotion
- Present for 8min with Powerpoint
- Schedule immediate follow-up meetings through on-target partnering
Who Should Apply
• Drug development
• Platform technology
• Medical device
• Digital health
Opportunities our audience are seeking
• Equity Investment
• Joint Venture
• And more…
Description: A leading biopharmaceutical company based in China with annual sales of $2.2 billion in 2017 and a market cap of $31 billion.
Recent Deal: Mycovia and Hengrui Medicine have signed an agreement to develop and commercialise the former’s investigational drug, VT-1161 for RVVC
Interests: oncology, autoimmune, metabolic and CV
Description: CSPC was recognized as the top brand for its compliance culture, ethical business and innovation
Recent Deal: Verastem grants CSPC exclusive rights to develop and commercialize the cancer drug Copiktra duvelisib in China.
Interests: Oncology, CV, Autoimmune
Description: Established innovative chemical drugs platform, biologics platform, high-value generic drugs platform and cell-therapy platform.
Recent Deal: Revance Therapeutics grants Fosun exclusive Chinese rights to RT002.
Interests: oncology, cardiovascular disease, CNS, liver disease, medical device
Description: Salubris is a globally integrated pharmaceutical group dedicated to the research, development, manufacture, marketing, distribution.
Recent Deal: Viracta Therapeutics Inc. granted Salubris exclusive rights to develop and sell its virus-related cancer therapy nanatinostat/valganciclovir in the great China.
Interests: Oncology, CV and metabolic diseases
Description: Luye Pharma is an international pharmaceutical company with a robust pipeline of 40 drug candidates in China and more than 10 drug candidates overseas.
Recent Deal: Luye Pharma and PharmaMar Sign Licensing Agreement for the Development and Commercialization of Zepsyre® in China.
Interests: Oncology, CNS, CV, diabetes, digestive disease and metabolic diseases
Description: A fully integrated pharmaceutical company focused on discovery, development, manufacturing and commercialization of medicines, with annual revenue of 4.5 billion USD.
Recent Deal: Huadong Medicine Co Ltd. Gains Access to Sinclair Pharma’s Highly Differentiated Aesthetics Products to Expand Business Beyond China into United States and Other Markets
Interests: Diabetes, Aesthetics, autoimmune disease, digestive disease, CV, oncology, and infectious disease.
More featured audience to be announced